$96.43
+0.24%
N/A+$0.23
Healthcare
Biotechnology
NASDAQ
활발히 거래 중
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the ...
B
Brian F. Sullivan
Celcuity Inc.
재임 기간 14y핵심 인물 리스크: High
Sullivan is an experienced, articulate operator who has successfully transitioned from tech/med-tech to biotech. His leadership is currently driving Celcuity toward potential clinical milestones, and his track record of exits...
핵심 위험
•Clinical trial failure
•Cash burn
•Key-man risk
핵심 순풍
•Positive recent data for lead asset
•Strong institutional support
•Strategic focus on high-value precision oncology
B
Brian F. Sullivan
Celcuity Inc. (CELC) · NASDAQ
American재임 기간 14 년창업자 CEO핵심 인물 리스크: High
AB in Economics, magna cum laude with distinction, Harvard College
출신 배경
A serial entrepreneur with a background in tech and medical devices, Sullivan co-founded Celcuity to solve complex cellular puzzles in cancer treatment.
어린 시절: Background in business and technology with over 25 years of experience in entrepreneurship and company building.
첫 기회: Co-founded Recovery Engineering, which he took public and sold to Procter and Gamble in 1999 for $265 million.
CEO가 되기까지: After the success of Recovery Engineering and leading Sterilmed as CEO until its $330M sale to J&J, he turned his focus to precision oncology, co-founding Celcuity in 2012 to apply a business-oriented, analytical approach to cancer therapeutics.
초기 비전: To create a 'hope company' by identifying abnormal cell-signaling networks to match cancer patients with the right targeted therapies.
Brian Sullivan is a proven serial entrepreneur who pivoted from medical devices to biotechnology. Following the successful exits of Recovery Engineering and Sterilmed, he applied his expertise in building businesses to the high-stakes world of precision oncology. He co-founded Celcuity in 2012, aiming to improve patient outcomes by treating cancer drug development as a complex puzzle-solving endeavor rather than traditional drug development. His leadership is marked by a blend of business-centric discipline and a deep commitment to addressing unmet needs in oncology, as demonstrated by the company's recent progress in breast cancer treatment.
serial entrepreneurbiotech founderproven exit track record
투자 관점
Sullivan is an experienced, articulate operator who has successfully transitioned from tech/med-tech to biotech. His leadership is currently driving Celcuity toward potential clinical milestones, and his track record of exits...
긍정 요인
Positive recent data for lead asset
Strong institutional support
Strategic focus on high-value precision oncology
핵심 리스크
Clinical trial failure
Cash burn
Key-man risk
경력
A highly successful serial entrepreneur with a track record of scaling and selling companies in the filtration and medical device sectors.
Celcuity Inc.
이니셔티브: Co-Founder, Chairman, CEO
기간: 2012–Present
사건: Led development of gedatolisib and precision oncology platform; consistent presence at major conferences like ASCO.
Sterilmed
이니셔티브: Chairman and CEO
기간: 2003–2011
사건: Scaled medical device operations; successfully sold to Johnson & Johnson for $330 million.
Recovery Engineering
이니셔티브: Co-Founder and CEO
기간: Pre-1999
사건: Took company public; sold to Procter and Gamble for $265 million.
successful exitsserial entrepreneurtech-to-biotech
회사 성과
The company remains in clinical development with significant recent data releases, though it is currently burning cash.
매출: Clinical-stage, no meaningful commercial revenue; net loss of $52.8M for Q1 2026.
수익성: N/A; currently burning cash to fund clinical trials.
주가: Volatility inherent to clinical-stage biotech; influenced by clinical data readouts (e.g., ASCO 2026).
•Positive ASCO 2026 data for gedatolisib
•Progress in HR+/HER2- breast cancer treatment
•Ongoing high operating expenses and cash burn
clinical-stager&d focuseddata-driven
경영 역량
Sullivan manages with a disciplined, puzzle-solving philosophy, attracting industry talent and maintaining a clear clinical focus.
스타일: Operator-led, disciplined, analytical
Sullivan brings an operator-centric style to a clinical-stage company, focusing heavily on execution and strategic clarity. He balances his non-scientific background by surrounding himself with strong technical talent (e.g., CSO Lance Laing) and commercial veterans. His management focus is on navigating complex clinical pathways and effectively communicating progress to investors, maintaining a high tempo of operations.
disciplined operatoranalyticalteam builder
자본 배분
Disciplined in capital use for high-impact clinical milestones, though still in a capital-intensive R&D phase.
Focuses capital primarily on pivotal clinical trials for lead assets.
As a serial entrepreneur, Sullivan maintains a disciplined approach to capital, focusing strictly on high-impact R&D. His previous exits demonstrate a clear history of disciplined value creation through company sales. At Celcuity, capital allocation is laser-focused on advancing the precision oncology platform and key assets toward regulatory and commercial readiness.
capital discipliner&d efficiency
자금 조달 및 파이낸싱
A proven ability to access capital markets to fuel long-term clinical development.
희석: Significant; standard for a clinical-stage biotech company.
Sullivan has successfully navigated the capital-intensive world of biotech, securing the funds necessary to advance multiple clinical programs. He maintains deep engagement with institutional investors and keeps a strong presence at major healthcare investment conferences, which is critical for sustaining long-term biotech R&D.
capital market experienceinvestor relationships
지배구조 및 통제
Standard corporate governance structures with a significant but not absolute insider influence.
Governance appears to follow standard public company norms. Sullivan serves as CEO and Chairman, indicating strong oversight, though the board includes several seasoned independent directors to provide checks and balances. Ownership is dispersed across institutional investors and insiders.
standard governanceboard oversight
건강 및 승계
No public concerns reported regarding health; typical key-man risk for a founder-led company.
건강 상태: no public concerns
핵심 인물 리스크: High
As a co-founder and the public face of the company for over 14 years, his departure would represent a significant transition for the company.
key-man risk
R&D 및 기술 비전
Visionary focus on identifying abnormal cellular signaling pathways as a superior way to treat cancer.
High; the entire company is focused on R&D.
Gedatolisib: Ongoing, with positive ASCO 2026 data
High; consistently focused on precision oncology and targeted therapies.
•Pivoting early to precision oncology targeting specific signaling pathways.
Sullivan’s tech vision is defined by a deep belief in precision medicine over traditional indiscriminate chemotherapy. He has steered the company into a strong competitive position by targeting unique pathways that other companies often overlook. The R&D roadmap is clear, milestone-driven, and highly focused, showing a strong ability to forecast medical market needs.
precision medicinestrategic foresight
인재 채용
Strong ability to attract high-caliber oncology commercial and clinical leaders to the team.
Chip Romp (Board): Veteran oncology commercial leader
Highly experienced and specialized bench strength.
유지율: strong
Sullivan places high importance on recruiting specialized talent to guide clinical strategy. His hiring of industry veterans—both for the executive team and the board—demonstrates an ability to build a bench that complements his own non-scientific background. He fosters a mission-driven culture that emphasizes solving complex problems.
talent magnetspecialized team
강점
Definitive strengths include his successful track record of exits and his ability to communicate complex ideas to investors.
Communication: Excellent ability to explain complex scientific topics to both scientific audiences and investors.
Track Record: Proven ability to scale and exit businesses as demonstrated by Sterilmed and Recovery Engineering.
communicatorproven operator
약점 및 실패
Potential key-man risk given his dual role as CEO and Chairman, and a lack of direct scientific background.
Governance
Dual role of CEO and Chairman can limit board independence.
key-man riskgovernance
마케팅 및 브랜드
Brand perception centers on being a 'hope company' that solves complex cancer-signaling riddles.
Shifted from a niche technology company to a credible clinical-stage oncology player in the eyes of the investor and medical community.
Sullivan effectively markets Celcuity not just as a drug developer, but as a scientific problem-solver. He frequently uses events like ASCO to build brand credibility among researchers and investors. His clear, narrative-driven communication style helps differentiate the company in a crowded biotech landscape.
narrative-driventhought leadership
PR 및 커뮤니케이션
Sullivan is an articulate, highly visible communicator who regularly presents to the investment community.
미디어 평판: positive
Sullivan has a high-quality reputation with the media and investors, being frequently cited in industry coverage as a reliable and clear spokesperson. He excels at explaining complex scientific pathways in accessible terms during earnings calls and conference presentations. His ability to maintain stakeholder confidence during the long clinical-stage process is a notable strength.
articulateinvestor-friendly
상류 / 하류 / 대체 기업